Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Inclusion Criteria: * Clinical diagnosis of T1D, diagnosed at least 12 months prior to enrollment * HbA1c ≥8.5%9 and \<14% on enrollment * Taking no medications known to affect blood glucose levels other than insulin. * Ability to provide participant written informed consent if age 18 years, or parental written informed consent and participant assent if participant is \< age 18 before any trial-related activities * Current regimen includes insulin detemir or I-glar, as long acting insulin * Willingness to use either I-glar or I-deg pens as basal insulin, and have school personnel supervise administration * Willingness to have school personnel supervise fasting blood β-hydroxybutyrate levels first thing in the morning at the beginning and end of each school week * Willingness to have school personnel supervise fasting blood glucose checks daily in the morning on school days, and eat breakfast after the fasting check Exclusion Criteria: * Female participants who are pregnant, breast-feeding or planning on becoming pregnant * Participant (and parent if age \<18) unable to read, write, and speak English. * Adolescents who are home schooled or no longer attending secondary school * Participant's school is unable to provide personnel to supervise injections of long-acting insulin or measurement blood glucose and β-hydroxybutyrate levels * Known or suspected allergy to trial medication(s), excipients, or related products. * Contraindications to study medications, including hypersensitivity to I-deg or one of its excipients, hypersensitivity to I-glar or one of its excipients, and administration of either during episodes of hypoglycaemia